Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Andrew Scott, SOE 2019 – The end of my YO journey

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 15th 2019

Andrew Scott discusses his experiences with the YO Committee, which came to an end at the SOE 2019. Dr Scott also previews the coming years, his achievements, and the SOE session he presented at SOE on Saturday.

Questions:
1. SOE 2019 was the end of your involvement with the SOE YO Committee. What were your highlights & what are you expecting to see in ophthalmology in the coming years? (0:04)
2. What are your best achievements as part of the YO Committee? (2:15)
3. Tell us about your YO session that you presented at SOE this year? (3:08)

Filmed in partnership with the European Society of Ophthalmology (SOE) at the SOE 2019 meeting in Nice, France.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup